MICHAEL LITTNER: Open Payments
NPI 1184071649 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,823 in 191 payments from 21 companies in 2025. Trend: 2023 $395 · 2024 $2,801 · 2025 $3,823
Food & beverage: $3,823
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 25 | $715 |
| ABBVIE INC. | 22 | $500 |
| Lundbeck LLC | 24 | $370 |
| Otsuka America Pharmaceutical, Inc. | 19 | $355 |
| Teva Pharmaceuticals USA, Inc. | 17 | $261 |
| E.R. Squibb & Sons, L.L.C. | 13 | $251 |
| Corium, LLC | 19 | $250 |
| Neurocrine BioSciences, Inc. | 8 | $238 |
| Janssen Pharmaceuticals, Inc | 8 | $218 |
| Alkermes, Inc. | 10 | $179 |
Products named: CAPLYTA, VRAYLAR, ABILIFY ASIMTUFII, REXULTI, COBENFY, Azstarys, INGREZZA, AUSTEDO XR.
Industry payments across NY — which companies pay providers there.
